AST-OPC1 — Competitive Intelligence Brief

AST-OPC1 (AST-OPC1) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: cell therapy. Area: Neurology.

phase 1 cell therapy Neurology Biologic

Target snapshot

AST-OPC1 (AST-OPC1) — Lineage Cell Therapeutics, Inc.. AST-OPC1 is a human oligodendrocyte progenitor cell therapy that promotes myelination and repair in spinal cord injuries.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
AST-OPC1 TARGET	AST-OPC1	Lineage Cell Therapeutics, Inc.	phase 1	cell therapy
Casgevy	EXAGAMGLOGENE AUTOTEMCEL		marketed	Autologous genome-edited hematopoietic stem cell therapy	BCL11A	2023-01-01
HPC, Cord Blood	HPC, Cord Blood	National Marrow Donor Program	marketed	Cell therapy; hematopoietic stem cell transplant
IL-7/IL-15 pre-treated CD19 cells	IL-7/IL-15 pre-treated CD19 cells	jiangjingting	marketed	CAR-T cell therapy	CD19
IL-2 pre-treated CD19 cells	IL-2 pre-treated CD19 cells	jiangjingting	marketed	Adoptive cell therapy	CD19
Mesenchymal Stem Cells (MSCs)	Mesenchymal Stem Cells (MSCs)	The Cleveland Clinic	marketed	Cell therapy
Autologous platelets rich plasma	Autologous platelets rich plasma	Mostafa Hassanein, Msc	marketed	Autologous cell therapy / Regenerative medicine product

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (cell therapy class)

1. Lisata Therapeutics, Inc. · 2 drugs in this class
2. Diakonos Oncology Corporation · 1 drug in this class
3. Lineage Cell Therapeutics, Inc. · 1 drug in this class
4. Steminent Biotherapeutics Inc. · 1 drug in this class